Themes / Cluster
Active · established relationshipLatest completed snapshot · Aug 21 · 16:11 ET

MARKET-DISCOVERED GROUP

Clinical Biotechnology

THE TRADER READShared activity without a clean directional read

3 of 5 measured session-normalized paths align to the downside across 3.9 effective names. Capital-flow agreement is 29%, so the basket is not yet clean. No verified headline preceded the measured move.

Price breadth2 up · 3 down-0.5% session-normalized median path
Capital-flow alignment29%Price breadth is not yet confirmed by flow
Activity nowNormalActivity score 54/100 · lift 1.0×
Evidence depth3 episodesLow sample—context, not a validated playbook
EVIDENCE CLOCK

What happened, in timestamp order

4 timed events · 15:40–15:55 ET
TIMING READNo verified timestamped headline was found within 24 hours of the first measured price move in the available common-bar window. The move currently reads as market-led or unexplained.
  1. 5-minute inferenceIDYA registered the first material upside path

    +1.98% session path at the threshold · IDYA

  2. 5-minute inferenceCELC registered a material upside path

    +3.07% session path at the threshold · CELC

  3. 5-minute inferenceRVMD registered a material downside path

    -0.40% session path at the threshold · RVMD

  4. 5-minute inferenceBCRX registered a material downside path

    -0.36% session path at the threshold · BCRX

2 earlier filing context receipts

MON, AUG 3IDYA filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

TUE, AUG 4BCRX filing documented shared operating contextproduct pipeline / R&D affecting expense · date precision only

Headline times and retained activity confirmations are point-in-time evidence. Price order is inferred from aligned 5-minute bars. Filing evidence has date precision only and is context, not an intraday catalyst claim.
THEME CONSTRUCTION

Broad move or one-stock disguise?

Session-normalized 5m paths

Observed movement is balanced across 3.9 effective names. CELC represents 33.3% of absolute path energy; 3 of 5 members align with the down relative path.

ConstructionBalanced33.3% from the largest path
Effective names3.9 / 5Movement diversity after concentration
Direction breadth3/5 aligneddownside relative path · 2 counter-moving
Largest moverCELC 33.3%62.6% from the top two paths
CELC33.3%Dominant mover · path +2.88% · basket +0.58pp
ABVX29.3%Dominant mover · path -2.54% · basket -0.51pp
IDYA21.9%Counter-move · path +1.90% · basket +0.38pp
RVMD9.4%Aligned contributor · path -0.81% · basket -0.16pp
BCRX6.0%Aligned contributor · path -0.52% · basket -0.10pp
Top six names by movement share are shown. Movement share measures absolute 5-minute path energy; signed basket contribution is equal-weight. Neither is a portfolio weight or causal attribution.

01 · WHAT IS HAPPENING

The move, the flow and who is driving it

Price breadth, unusual activity and signed capital flow are separate observations
HOW THE PRICE MOVE SPREAD

Observed session sequence

5-minute bars · inferred
  1. IDYA moved higher firstFirst member to clear the material path threshold · path +1.98%
  2. CELC registered a material higher path45m after the first price move · path +3.07%
  3. RVMD registered a material lower path70m after the first price move · path -0.40%
  4. BCRX registered a material lower path270m after the first price move · path -0.36%
  5. ABVX registered a material lower path295m after the first price move · path -0.71%

Sequence inferred from aligned 5-minute price paths; it is not a causal ordering.

RELATIVE CO-MOVEMENT

How the members are behaving together

Session-normalized
Aug 20 · 15:40 ETMove visible 09:30 ETAug 21 · 15:55 ET
Group median -0.52%Strongest relative path CELCWeakest relative path ABVX

Observed member paths normalized to the session. The dashed marker shows when the median move first cleared a material threshold; shading marks the latest 20% of the observed window.

02 · WHY IT MATTERS

Why now and where the move could travel

Context and lead/lag links are evidence, not proof of causation or a forecast
WHY NOW

Verified recent context

0 items

No verified recent catalyst is attached to this move. The relationship may be market-led rather than news-led.

WHY THIS GROUP EXISTS

Shared filing context

4/5 members covered

Moderate filing support: the strongest shared 10-Q/K outlook is operating setup (near-term outlook) across BCRX, CELC, IDYA, RVMD.

product pipeline / R&D affecting expense

“Research and Development Expenses Research and development expenses increased by $13.0 million, or 14% during the three months ended June 30, 2026 compared to the three months ended March 31, 2026 primarily due to $11.2 million in fees paid to CROs and consultants related to the advancement of our lead product candidates through preclinical and clinical studies and $1.8 million in personnel-related expenses, including salaries, benefits and stock-based compensation, to support our growth and research and development programs.”

IDYA 10-Q · 2026-08-04
credit / rates affecting interest expense

“These items were partially offset by $731.4 million of non-cash items, primarily related to $697.8 million of acquired in-process research and development expense, $16.0 million of stock-based compensation expense, $13.3 million of non-cash interest expense on royalty financing obligations, and a $2.8 million of mark-to-market adjustment related to our share-based liability.”

BCRX 10-Q · 2026-05-06
product pipeline / R&D affecting revenue

“Comparison of Three Months Ended June 30, 2026 and March 31, 2026 The following table summarizes our results of operations for the periods indicated (in thousands): Three Months Ended June 30, 2026 March 31, 2026 Change % Change Revenue: Collaboration revenue $ 8,857 $ 6,560 $ 2,297 35 % Operating expenses: Research and development 108,689 95,726 12,963 14 % General and administrative 22,459 19,378 3,081 16 % Loss from operations (122,291 ) (108,544 ) (13,747 ) (13 %) Interest income and other income, net 9,839 10,005 (166 ) (2 %) Net loss $ (112,452 ) $ (98,539 ) $ (13,913 ) (14 %) Collaboration Revenue Collaboration revenue increased by $2.3 million, or 35%, during the three months ended June 30, 2026 compared to the three months ended March 31, 2026 as a result of revenue recognized from the Servier License Agreement.”

IDYA 10-Q · 2026-08-04
CONFIRMATION NETWORK

Outsiders and cross-asset links

0 outsiders confirming
ABG → UVXYPositive historical lead/lag · strength 0.34
ABG → SLVInverse historical lead/lag · strength -0.28

Filing-linked outsiders test whether the move is spreading beyond the established cohort.

ABCLNot confirming

RVMD · text peer

ACRSNot confirming

RVMD · text peer

ERNANot confirming

RVMD · text peer

EXELNot confirming

RVMD · text peer

03 · WHO IS IN IT

Member participation

Unusual activity and daily price direction are shown separately
IDYAABVXBCRXRVMDCELC

5/5 active2 rising · 3 falling

MemberUnusual activityToday's moveRead now
IDYAIDEAYA Biosciences, Inc.
Most unusual · 100/100
+1.5%
Counter-move / dispersionActive in 28.6% of observed group sessions
ABVXABIVAX Société Anonyme
Elevated · 78/100
-2.8%
Dominant path moverActive in 14.3% of observed group sessions
BCRXBioCryst Pharmaceuticals, Inc.
Elevated · 50/100
-1.1%
Aligned price + flowActive in 0% of observed group sessions
RVMDRevolution Medicines, Inc.
Elevated · 38/100
-1.1%
Aligned price + flowActive in 57.1% of observed group sessions
CELCCelcuity Inc. Common Stock
Elevated · 34/100
+3.4%
Dominant path moverActive in 14.3% of observed group sessions
View exact member values
TICKERCompanyRole nowTodayObserved historyTrader interpretation
IDYAIDEAYA Biosciences, Inc.Most unusual+1.5%28.6% of 7 sessionsMost unusual activity in this snapshot; performance direction may differ.
ABVXABIVAX Société AnonymeParticipating-2.8%14.3% of 7 sessionsPrice participation with accumulating signed flow.
BCRXBioCryst Pharmaceuticals, Inc.Participating-1.1%0% of 7 sessionsPrice participation with accumulating signed flow.
RVMDRevolution Medicines, Inc.Participating-1.1%57.1% of 7 sessionsPrice participation with accumulating signed flow.
CELCCelcuity Inc. Common StockParticipating+3.4%14.3% of 7 sessionsPrice participation with accumulating signed flow.

04 · HAS THIS HAPPENED BEFORE

Identity history versus measured outcomes

Structural recurrence is not the same as a validated trading outcome
POINT-IN-TIME LIVE OUTCOMES

Early observed follow-through

2/2 events completed
30 minutes+1.51%100% continuation · n=1Median MFE +2.30% · MAE 0.04%
60 minutes+1.27%100% continuation · n=1Median MFE +2.30% · MAE 0.04%
Session close+0.52%100% continuation · n=1Median MFE +2.30% · MAE 0.04%
Next-session close+1.41%100% continuation · n=1Median MFE +2.30% · MAE 0.04%
Only point-in-time live watcher observations and conservative same-day EOD observations are included. Later backfills and replay runs are excluded.
Low structural sample

Only 3 completed episodes across 7 active sessions; treat history as context, not a validated playbook. These episode counts describe recurrence; the outcome ledger above is the only forward-performance evidence.

Structural support17 daysHow often the cohort identity was observed
Completed episodes3Separate periods of broad group activity
Active sessions7Completed session observations, not trades
2026-08-181 active session100% composition consistency through the episode
2026-08-131 active session100% composition consistency through the episode
2026-07-27 → 2026-08-055 active sessionsNo name was active through every recorded session
MEMBER CONSISTENCY IN OBSERVED ACTIVE SESSIONS
RVMD57.1% · 1 episode
IDYA28.6% · 2 episodes
ABVX14.3% · 1 episode
CELC14.3% · 1 episode
BCRX0% · 0 episodes